# Lexaria (NASDAQ: LEXX) Validates Tech’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released findings from its applied research program that sought to evaluate the mode of action facets of its patented DehydraTECH(TM) technology and the glucagon-like peptide 1 (“GLP-1”) drug, semaglutide. The program was conducted in conjunction with the National Research Council of Canada (“NRC”), […] 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/lexaria-nasdaq-lexx-validates-techs-superiority-moving-closer-to-a-share-in-the-global-diabetes-treatment-market/)
                    

[Newsramp.com TLDR](None) 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1f2hcte/lexaria_bioscience_releases_findings_from/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/mint5cs6.webp)